Trial Profile
RIVA-PCI Registry - Prospective Registry of Rivaroxaban in Patients With Atrial Fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Coronary thrombosis; Ischaemia; Stroke
- Focus Therapeutic Use
- Acronyms RIVA-PCI
- 06 Dec 2022 Results (n=700; of two studies RIVA-PCI and PIONEER-AF PCI) comparing the efficacy and safety of rivaroxaban in patients with atrial fibrillation (AF) who underwent percutaneous coronary intervention (PCI) in clinical practice published in the American Journal of Cardiology
- 30 Mar 2022 Status changed from active, no longer recruiting to completed.
- 01 Jul 2021 Planned End Date changed from 1 May 2021 to 1 Oct 2021.